z-logo
Premium
Preserved Response to Diuretics in Rosiglitazone‐Treated Subjects With Insulin Resistance: A Randomized Double‐Blind Placebo‐Controlled Crossover Study
Author(s) -
Rennings AJ,
Russel FG,
Li Y,
Deen PM,
Masereeuw R,
Tack CJ,
Smits P
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.360
Subject(s) - furosemide , epithelial sodium channel , amiloride , natriuresis , rosiglitazone , endocrinology , medicine , crossover study , downregulation and upregulation , insulin resistance , placebo , chemistry , pharmacology , insulin , kidney , sodium , biochemistry , alternative medicine , organic chemistry , pathology , gene
Thiazolidinediones (TZDs) are associated with fluid retention that has been suggested to be resistant to treatment with loop diuretics. This resistance is thought to be caused by upregulation of renal epithelial sodium channels (ENaCs). In this study, we tested whether these mechanisms are of clinical significance. We conducted a well‐controlled study in 12 insulin‐resistant nondiabetic participants, who received treatment for 9 weeks with either rosiglitazone at a dosage of 4 mg b.i.d. or placebo. The aim of the study was to investigate whether upregulation of ENaCs by rosiglitazone reduces furosemide's natriuretic response and enhances the response to the ENaC inhibitor amiloride. The natriuretic response to furosemide and amiloride and the amount of α‐ENaC in urinary exosomes were quantified. Rosiglitazone neither reduced furosemide‐induced natriuresis nor changed furosemide's concentration–effect curve. Furthermore, rosiglitazone did not change either amiloride‐induced natriuresis nor the amount of urinary α‐ENaC. This study challenges previous findings regarding TZD‐related ENaC upregulation and suggests that TZD‐induced fluid retention should respond normally to loop diuretics. Clinical Pharmacology & Therapeutics (2011) 89 4, 587–594. doi: 10.1038/clpt.2010.360

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here